Kisspeptin-10: The Upstream Master Switch of Fertility
Last updated: March 2026
Kisspeptin-10 is the master upstream regulator of the entire reproductive axis — a 10-amino acid neuropeptide that activates GnRH neurons to trigger LH surges. As an IVF trigger, it achieves comparable oocyte maturation to hCG while dramatically reducing dangerous ovarian hyperstimulation syndrome risk.
As IVF Trigger
vs. hCG Trigger
IV Bolus
📋 On this page
How Kisspeptin-10 Works
Kisspeptin sits at the top of the reproductive hormonal hierarchy — acting even above GnRH. By activating hypothalamic GnRH neurons, it generates a physiologic LH surge that is time-limited and self-terminating, unlike the prolonged hCG exposure that causes OHSS.
Kisspeptin-10 binds the KISS1 receptor (GPR54) on hypothalamic GnRH neurons. This G-protein coupled receptor triggers intracellular calcium release and membrane depolarization in GnRH neurons, causing coordinated pulsatile GnRH secretion from the arcuate nucleus and anteroventral periventricular nucleus.
Kisspeptin neurons are the primary integrators of metabolic, seasonal, and steroidal signals that regulate reproduction. Estrogen acts on kisspeptin neurons to generate the preovulatory LH surge. By administering exogenous kisspeptin, researchers can recapitulate this surge on demand — the basis for its use as an IVF trigger.
Unlike hCG (which has a 36-hour half-life and causes sustained LH-receptor activation), kisspeptin triggers an endogenous LH surge that follows natural physiologic kinetics — rising rapidly then declining over 24–36 hours. This shorter hormonal exposure reduces cumulus cell desensitization and dramatically lowers OHSS risk in high-risk patients.
Kisspeptin neurons also integrate energy balance signals — leptin and insulin act on kisspeptin neurons to communicate nutritional status to the reproductive axis. This is why starvation suppresses reproduction and why women with hypothalamic amenorrhea have low kisspeptin tone. Research into kisspeptin as a therapeutic for functional hypothalamic amenorrhea is ongoing.
What the Clinical Trials Show
Data primarily from Phase 1/2 trials at Imperial College London (Dhillo et al., 2005–2023) and subsequent IVF trigger studies.
Side Effects & Risks
Key Takeaways
- Kisspeptin-10 is the physiologic master upstream activator of GnRH neurons
- IV kisspeptin triggers robust LH surges in 100% of healthy subjects studied
- As IVF trigger: ~95% oocyte maturation — comparable to hCG
- ~90% reduction in moderate/severe OHSS in high-risk patients vs. hCG
- Self-terminating LH surge kinetics explain the OHSS safety advantage
- Live birth rates in Phase 2 studies are comparable to hCG trigger
- Optimal dosing for subcutaneous vs. IV administration in IVF
- Long-term safety data and regulatory approval timeline
- Efficacy in male fertility applications (hypogonadism, low sperm count)
- Whether kisspeptin analogs with longer half-lives will outperform native peptide
🔬 Verified Research Source
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports HighPeptides at no extra cost. All Swiss Chems products include third-party lab testing certificates.
🛒 Recommended Products
Testing and monitoring supplies relevant to fertility and hormone tracking.
Research-Grade Peptides
Third-party tested compounds with certificates of analysis. Used by researchers worldwide.
Browse Swiss Chems →Affiliate link — supports HighPeptides at no extra cost.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This page is for educational purposes only. It is not medical advice. Kisspeptin-10 is an investigational compound not approved by the FDA or EMA as of 2026. Its use is limited to clinical research settings and specialist fertility centers. Do not self-administer investigational peptides. Consult a board-certified reproductive endocrinologist for fertility treatment options.